Literature DB >> 27754817

Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.

Silvia Gómez-Zorrilla1, Francisco Morandeira2, María José Castro3, Fe Tubau4, Elisabet Periche5, Rosario Cañizares5, María Angeles Dominguez4, Javier Ariza1, Carmen Peña1.   

Abstract

The severity of Pseudomonas aeruginosa (PA) infection may be determined by the interaction with the host immune system. We designed a prospective study to assess the relationship between the inflammatory response and the clinical presentation and outcome of PA infection. We also investigated whether there are differences in the inflammatory response depending on the resistance profile of PA. Interleukin-6 (IL-6), IL-10, procalcitonin (PCT), and C-reactive protein (CRP) were measured. Sixty-nine infection episodes were recorded; 40 caused by non-multidrug-resistant (non-MDR) strains [29 (73%) respiratory; 8 (20%) bacteremia], 12 by MDR non-extensively drug-resistant (MDR-non-XDR) [9 (75%) respiratory; 3 (25%) bacteremia], and 17 by XDR strains [9 (53%) respiratory; 7 (41%) bacteremia]. All inflammatory parameters were significantly higher in patients who developed acute organ dysfunction and bacteremia. PCT levels were higher in patients with early mortality [p = 0.050]. Inflammatory biomarkers were higher in patients with XDR than in those with non-MDR PA [IL-6 430 (67-951) vs. 77 (34-216), p = 0.02; IL-10 3.3 (1.5-16.3) vs. 1.3 (0-3.9), p = 0.02; and PCT 1.1 (0.6-5.2) vs. 0.3 (0.1-1.0), p = 0.008]. The intensity of inflammatory response was associated with the severity of PA infection, particularly if bacteremia occurred. Only PCT was documented useful to predict the outcome. XDR infections presented a higher inflammatory response; related in part to the larger number of bloodstream infections in this group.

Entities:  

Keywords:  Pseudomonas aeruginosa; infections; microbial drug resistance; nosocomial infections

Mesh:

Substances:

Year:  2016        PMID: 27754817      PMCID: PMC5488258          DOI: 10.1089/mdr.2016.0144

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  36 in total

1.  Endotoxin, cytokines, and procalcitonin in febrile patients admitted to the hospital: identification of subjects at high risk of mortality.

Authors:  P van Langevelde; K Joop; J van Loon; M Frölich; P H Groeneveld; R G Westendorp; J T van Dissel
Journal:  Clin Infect Dis       Date:  2000-11-29       Impact factor: 9.079

2.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Authors:  Cheol-In Kang; Sung-Han Kim; Hong-Bin Kim; Sang-Won Park; Young-Ju Choe; Myoung-Don Oh; Eui-Chong Kim; Kang-Won Choe
Journal:  Clin Infect Dis       Date:  2003-08-23       Impact factor: 9.079

3.  Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis.

Authors:  Marcin F Osuchowski; Judith Connett; Kathleen Welch; Jill Granger; Daniel G Remick
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

4.  Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.

Authors:  Carmen Peña; Gabriel Cabot; Silvia Gómez-Zorrilla; Laura Zamorano; Alain Ocampo-Sosa; Javier Murillas; Benito Almirante; Virginia Pomar; Manuela Aguilar; Ana Granados; Esther Calbo; Jesús Rodríguez-Baño; Fernando Rodríguez-López; Fe Tubau; Luis Martínez-Martínez; Antonio Oliver
Journal:  Clin Infect Dis       Date:  2014-11-06       Impact factor: 9.079

5.  Serum procalcitonin is a sensitive marker for septic shock and mortality in secondary peritonitis.

Authors:  Guntars Pupelis; Nadezda Drozdova; Maksims Mukans; Manu L N G Malbrain
Journal:  Anaesthesiol Intensive Ther       Date:  2014 Sep-Oct

6.  Systemic cytokine response in patients with community-acquired pneumonia.

Authors:  H Endeman; S C A Meijvis; G T Rijkers; H van Velzen-Blad; C H M van Moorsel; J C Grutters; D H Biesma
Journal:  Eur Respir J       Date:  2010-09-30       Impact factor: 16.671

Review 7.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

8.  Compartmentalized cytokine production within the human lung in unilateral pneumonia.

Authors:  M S Dehoux; A Boutten; J Ostinelli; N Seta; M C Dombret; B Crestani; M Deschenes; J L Trouillet; M Aubier
Journal:  Am J Respir Crit Care Med       Date:  1994-09       Impact factor: 21.405

9.  Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response.

Authors:  O Sibila; C Agustí; A Torres; S Baquero; S Gando; J R Patrón; J G Morato; D H Goffredo; N Bassi; C M Luna
Journal:  Eur Respir J       Date:  2007-09-05       Impact factor: 16.671

10.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.

Authors:  J W Chow; M J Fine; D M Shlaes; J P Quinn; D C Hooper; M P Johnson; R Ramphal; M M Wagener; D K Miyashiro; V L Yu
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

View more
  4 in total

1.  Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages.

Authors:  Wan-Kyu Ko; Soo-Hong Lee; Sung Jun Kim; Min-Jae Jo; Hemant Kumar; In-Bo Han; Seil Sohn
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

2.  Increased Plasma Levels of Mitochondrial DNA and Normal Inflammasome Gene Expression in Monocytes Characterize Patients With Septic Shock Due to Multidrug Resistant Bacteria.

Authors:  Stefano Busani; Sara De Biasi; Milena Nasi; Annamaria Paolini; Sophie Venturelli; Martina Tosi; Massimo Girardis; Andrea Cossarizza
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

3.  Anti-inflammatory effect of Tauroursodeoxycholic acid in RAW 264.7 macrophages, Bone marrow-derived macrophages, BV2 microglial cells, and spinal cord injury.

Authors:  Seong Jun Kim; Wan-Kyu Ko; Min-Jae Jo; Yoshie Arai; Hyemin Choi; Hemant Kumar; In-Bo Han; Seil Sohn
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

Review 4.  Expanding the Current Knowledge About the Role of Interleukin-10 to Major Concerning Bacteria.

Authors:  Hernán F Peñaloza; Loreani P Noguera; Claudia A Riedel; Susan M Bueno
Journal:  Front Microbiol       Date:  2018-09-18       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.